June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Risk Factors for Persistent Avascular Retina Following Bevacizumab Therapy for Retinopathy of Prematurity
Author Affiliations & Notes
  • Hailey Kay Robles-Holmes
    University of Miami School of Medicine, Miami, Florida, United States
  • J. Peter Campbell
    Oregon Health & Science University, Portland, Oregon, United States
  • Eric Nudleman
    University of California at San Diego Department of Ophthalmology at the Shiley Eye Institute, La Jolla, California, United States
    Rady Children's Hospital San Diego, San Diego, California, United States
  • Footnotes
    Commercial Relationships   Hailey Robles-Holmes None; J. Peter Campbell Boston AI labs, Code C (Consultant/Contractor), Genentech, Code F (Financial Support), Siloam Vision, Code O (Owner); Eric Nudleman Alcon, Regeneron, Roche/Genentech, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4197 – F0257. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hailey Kay Robles-Holmes, J. Peter Campbell, Eric Nudleman; Risk Factors for Persistent Avascular Retina Following Bevacizumab Therapy for Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4197 – F0257.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Peripheral retinal vascularization continues following treatment with bevacizumab (IVB) for type 1 Retinopathy of Prematurity (ROP). However, many eyes have persistent avascular retina (PAR) despite therapy, which may lead to late reactivation, retinal detachment, and blindness. We aimed to identify risk factors for PAR following bevacizumab therapy for type 1 ROP.

Methods : We conducted a retrospective series of 106 eyes from 53 infants with type 1 ROP. 74 eyes from 37 infants received IVB with subsequent laser of PAR at an average of 49.5 weeks postmenstrual age (PMA) 95% CI [45.7, 53.2] (Group 1). 20 eyes from 10 infants were treated with IVB and did not receive subsequent laser (Group 2). Fundus photos were available for 52 eyes of 26 infants in Group 1 and from 14 eyes of 7 infants in Group 2. We compared the patient demographics, timing of treatment, and the fundus photographs at the time of IVB and laser photocoagulation. Length and rate of vascular growth after IVB were measured. In addition, we measured changes in vascular severity score (VSS) following IVB, which provides an objective assessment of disease severity.

Results : The average length of vascular growth following IVB was 100.7 millimeters (mm), 95% CI [86.2, 115.1] over an average of 80.4 days, 95% CI [70.3, 90.4]. Group 2 had higher birthweight (BW) (p<0.05), greater extent of retinal vascularization at time of IVB (p<0.001), and lower VSS at time of IVB (p<0.01) than Group 1. Zone/Stage, gestational age (GA), and post-menstrual age (PMA) at time of IVB did not differ significantly between Group 1 and Group 2. The overall mean VSS decreased significantly following IVB in all Group 1 eyes (p<0.001). The amount of VSS change from time of IVB to time of laser was positively correlated with the extent of vascular growth following IVB (p<0.05), providing a potential biomarker for PAR.

Conclusions : The presence of PAR requiring laser after IVB was associated with lower BW, more posterior disease, and higher VSS at the time of IVB. In addition, a larger VSS change following IVB was significantly associated with increased vascular growth. VSS may provide a tool for predicting PAR and monitoring for arrest of vascularization.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×